BioSpace News Archive

Business

Biogen Halts ALS Asset Agreement with Karyopharm

Biogen has terminated its asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being evaluated as a treatment for ALS.

June 16, 2022
·
2 min read
·
Vanessa Doctor, RN
Policy

FDA Sets Hearing Date for Covis’ Beleaguered Preterm Birth Drug

Covis announced that the U.S. Food and Drug Administration has granted the company a hearing for its controversial drug Makena, which is intended to reduce preterm births.

June 16, 2022
·
2 min read
·
Hayley Shasteen
Business

Pfizer Makes Supportive Investment in Akero’s NASH Drug

Shares of Akero Therapeutics are surging after the company announced pharma giant Pfizer made a $25 million equity investment to support the development of the company’s experimental liver drug.

June 16, 2022
·
3 min read
·
Alex Keown
Policy

Trial Automation, Education Lapse Consequences of COVID-19 for Cancer Research

Frederick National Laboratories, the American Cancer Society and other leaders are picking up the pieces - both good and bad - as COVID-19 becomes endemic.

June 16, 2022
·
2 min read
·
Hannah Chudleigh
Business

BioSpace Movers & Shakers: ADC, Akari, Scorpion & More

This week’s Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.

June 16, 2022
·
8 min read
·
Alex Keown
Research Roundup: Science One Step Closer to Growing Organs in a Dish

Although it seems like science fiction, we may one day be able to grow replacement organs and tissues. For that and more reach news, continue reading.

June 16, 2022
·
4 min read
·
Mark Terry
Business

ADC Space Continues to Thrive with Four More Companies Linking Up

This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.

June 16, 2022
·
3 min read
·
Tristan Manalac
Drug Development

Roche Therapy for Rare Form of Alzheimer’s Falls Short in Phase III

The trial evaluated crenezumab’s ability to slow Alzheimer’s disease in cognitively unimpaired people with a specific gene mutation that causes early-onset Alzheimer’s disease.

June 16, 2022
·
3 min read
·
Mark Terry
Business

Kyowa Kirin Could Sell $1B in Assets as it Advances PI3K Inhibitor

According to reports citing “people familiar with the matter,” Kyowa Kirin, a specialty pharma company, could be lining up the sale of $1 billion worth of assets on the international market.

June 16, 2022
·
2 min read
·
Mark Terry
“Holy Grail” Transplantation Technique Offers Hope to Patients with Rare Kidney Disease

In a study conducted by researchers at Stanford University, three pediatric patients with a rare genetic disease that often results in kidney failure received kidney transplants.

June 16, 2022
·
2 min read
·
Jazmine Colatriano, M.S.